News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News Pfizer's antibody drug trial misses key survival target in A... Inotuzumab ozogamicin missed one of two endpoints in trial.
Views & Analysis Pharma data collaboration speeds R&D Historic clinical trial data represent a valuable and, until now, relatively untapped resource that could accelerate research and development of new drugs.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
